摘要
目的 观察对比比索洛尔、依那普利联合螺内酯治疗风湿性心脏病慢性心力衰竭患者的有效性。方法 选取2015年6月-2016年6月我院收治的94例风湿性心脏病慢性心力衰竭患者作为研究对象,随机均分为实验组与对照组,每组各47例。对照组患者给予常规药物治疗,实验组患者则采用比索洛尔、依那普利联合螺内酯治疗,观察并比较两组患者的治疗效果。结果 实验组患者总有效率为95.75%（45/47）,明显高于对照组的82.98%（39/47）,差异有统计学意义（P〈0.05）;治疗后,实验组患者的LVESD、LVEDD及LVEF水平均明显优于对照组,差异有统计学意义（P〈0.05）。结论 采用比索洛尔、依那普利及螺内酯联合治疗风湿性心脏病慢性心力衰竭效果较好,值得进行进一步的研究及应用。
Objective To observe and compare the efficacy of Bisoprolol and Enalapril combined with Spironolactone in the treatment of rheumatic heart disease patients with chronic heart failure.Methods From June 2015 to June 2016,94 patients with rheumatic heart disease and chronic heart failure were selected as study objects and randomly divided in- to experimental group and control group,47 cases in each group.The patients in the control group were given routine drug treatment,while patients in the experimental group were treated with Bisoprolol and Enalapril combined with Spironolactone.The therapeutic effect of two groups were observed and compared.Results After treatment,the total effective rate in the experimental group was 95.75% （45/47）,which was significantly higher than 82.98% （39/47） in the control group,and the difference was statistically significant （P〈0.05）.The LVESD, LVEDD and LVEF of the experimental group was significantly better than that of the control group,and the difference was statistically significant （P〈0.05）. Conclusion The combination of Bisoprolol,Enalapril and Spironolactone is effective in the treatment of rheumatic heart disease with chronic heart failure.It is worthy to be further studied and applied.
出处
《中国当代医药》
2016年第35期49-51,共3页
China Modern Medicine
